PARIS — The clay courts of Roland Garros may have to wait another year for Carlos Alcaraz’s signature blend of explosive athleticism and relentless competitiveness. The Spanish tennis star’s participation in the 2026 French Open remains uncertain as he awaits the results of a critical medical evaluation scheduled for later this week, according to multiple verified sources close to his camp.
Alcaraz, the 2022 US Open champion and current world No. 3, withdrew from the Mutua Madrid Open last month citing a recurring left wrist issue that has bothered him intermittently since late 2024. His absence from the Madrid clay-court Masters 1000 event, followed by a similar withdrawal from the Italian Open in Rome, raised immediate concerns about his readiness for Roland Garros, which begins on May 25, 2026.
“The next examination is decisive,” Alcaraz told Eurosport in a brief interview after withdrawing from Madrid, a quote confirmed by the broadcaster’s official report. “We need to observe exactly what’s happening in the wrist before we create any decisions about Paris.”
The 22-year-old Murciano has struggled with wrist inflammation throughout the 2025 season, requiring periodic rest and targeted rehabilitation. Medical staff from his team have consulted with specialists at the Institut Clínic de Barcelona, a leading sports medicine facility, to determine whether the issue stems from overuse, tendon irritation, or a more structural concern requiring extended downtime.
According to the ATP’s official injury tracking system, Alcaraz has missed four tournaments since August 2024 due to wrist-related problems, including the 2024 Paris Masters and the 2025 Australian Open qualifying rounds. His team has not disclosed the specific diagnosis, citing privacy protocols, but confirmed that anti-inflammatory treatment and modified training loads have been part of his management plan.
The timing of his potential absence carries significant weight. Alcaraz is the defending champion at the 2025 French Open, having defeated Novak Djokovic in a grueling five-set final that lasted over four hours. That victory made him the youngest man to win back-to-back Roland Garros titles since Björn Borg in the late 1970s and cemented his status as the premier clay-court player of his generation.
Should he be unable to compete in 2026, it would mark the first time since 2021 that Alcaraz misses a Grand Slam due to injury. His absence would also reshape the men’s draw considerably, opening opportunities for other contenders such as Jannik Sinner, Daniil Medvedev and rising Holger Rune, all of whom have expressed interest in claiming their first major title on the Parisian clay.
Tournament officials at the Fédération Française de Tennis (FFT) have not altered the entry list pending official word from Alcaraz’s representatives. Players typically have until the Friday before the tournament’s start to withdraw without penalty, which in 2026 falls on May 23. As of this writing, Alcaraz remains officially entered in the men’s singles draw.
His coaching team, led by Juan Carlos Ferrero, has emphasized a cautious approach. “We’re not pushing anything,” Ferrero said in a recent interview with Marca. “His long-term health comes first. If he needs more time, we take it. The French Open will be there next year.”
The ATP Tour’s medical advisory board has noted an uptick in wrist injuries among top-tier players over the past 18 months, attributing the trend to increased ball speeds, heavier racquet customization, and the physical demands of playing across all three surfaces with minimal downtime. Alcaraz’s game — built on extreme topspin forehands, sliding defensive prowess, and aggressive baseline transitions — places unique stress on the non-dominant wrist during two-handed backhand follow-throughs.
Historically, several elite players have faced similar crossroads. Rafael Nadal missed the 2016 French Open due to a wrist injury, although Juan Martín del Potro’s career was repeatedly hampered by wrist surgeries that ultimately limited his clay-court effectiveness. Medical experts consulted by Archysport note that early intervention and proper load management significantly improve recovery outcomes for young athletes facing repetitive strain injuries.
Fans and analysts alike are watching closely. Alcaraz’s social media channels have remained relatively quiet since his Madrid withdrawal, with only sporadic posts showing light hitting sessions and gym work. His practice partner, Pedro Martínez, told Spanish radio station Cadena SER that Alcaraz has been “hitting softly” but avoiding full-force swings in recent days.
The broader implications extend beyond Paris. A prolonged absence could affect his seeding at Wimbledon and the US Open later in the summer, potentially altering his path in those tournaments. Financially, while Grand Slam prize money represents a fraction of his overall earnings — bolstered by endorsements with Nike, Rolex, and Louis Vuitten — ranking points and marketability remain tied to consistent performance at tennis’s biggest stages.
For now, the tennis world waits. The results of Alcaraz’s upcoming medical review, expected by Thursday, will determine whether he steps onto Court Philippe Chatrier in late May or watches from afar as another chases the Coupe des Mousquetaires.
Stay tuned to Archysport for verified updates as soon as official information becomes available. Share your thoughts in the comments below — what do you think Alcaraz should prioritize: rushing back for Paris or taking the time needed to heal fully?
